Abstract
Objectives: 1) How well do the short forms previously developed from the Maternal Opioid Treatment: Human Experimental Research (MOTHER) neonatal abstinence syndrome (NAS) scale (MNS) discriminate between neonates untreated and treated for NAS? (2) Can a short form be developed that is superior to other short forms in discriminating between the two groups? Design/participants: This secondary analysis study used data from 131 delivered neonates in the MOTHER study, a randomized controlled trial comparing neonatal and maternal outcomes in opioid-dependent pregnant women administered buprenorphine or methadone. Setting: Comprehensive care was provided at seven university hospitals. Outcome measures: A 19-item instrument measuring neonatal abstinence signs. Results: A five-item index proved superior to the previous indices (ps<0.01) and discriminated between the treated and untreated NAS groups as well as did the MNS total score (p=0.09). Conclusions: A short form developed from the MNS shows promise as a possible screening measure.
Original language | English (US) |
---|---|
Pages (from-to) | 19-23 |
Number of pages | 5 |
Journal | Journal of opioid management |
Volume | 12 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2016 |
Keywords
- MOTHER NAS scale
- Neonatal abstinence syndrome
- Opioid use disorder
- Pregnancy
ASJC Scopus subject areas
- Pharmacology (medical)
- Anesthesiology and Pain Medicine